Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in erythrocyte progenitors | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16952
Sealed predictions
- SPECC1 in microglia, braak+0.02 (p 0.964) → -0.56 (p 0.118)receipt 16959
- SPECC1 in dopamine neurons, braak+0.80 (p 0.009) → -0.25 (p 0.520)receipt 16960
Swarm cases
receipt 16960: SPECC1 in dopamine neurons, braak
- power
- full sample +0.22 (p 0.374, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.408, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.26 (p 0.298, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.35, sign flips 0; without severely affected donors +0.22 (p 0.374, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.64 (p 0.0045, n 18) vs +0.22 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SPECC1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SPECC1 · oligodendrocytes · braak: substantia nigra, an independent cohort (already registered)
receipt 16959: SPECC1 in microglia, braak
- power
- full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.30 (p 0.232, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.22, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.64 (p 0.0045, n 18) vs -0.28 in microglia. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SPECC1 in microglia.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SPECC1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 1.4e-4)
Receipts
loading the receipts